AbbVie Q1 Beat: Skyrizi, Rinvoq Drive 2026 Growth!

AbbVie Q1 Beat: Skyrizi, Rinvoq Drive 2026 Growth!

Introduction
AbbVie reported a first-quarter performance that matters for investors: an earnings beat coupled with a raised full-year adjusted EPS outlook. The surprise strength came from AbbVie’s newer immunology portfolio — notably Skyrizi and Rinvoq — which continue to compensate for ongoing Humira erosion. Recent analyst upgrades, regulatory filings and a major manufacturing investment together make this an operationally significant week for ABBV stock.

What the Q1 results reveal

AbbVie’s Q1 results underscore a clear revenue shift within the company. While Humira’s legacy sales continue to decline as biosimilars gain traction globally, Skyrizi and Rinvoq posted robust growth that materially impacted the headline numbers and management’s guidance.

Key sales data

• Skyrizi (risankizumab) delivered about $4.48 billion in sales, up roughly 31% year-over-year, slightly above consensus expectations.
• Rinvoq (upadacitinib) generated roughly $2.12 billion, increasing about 23% year-over-year and also topping estimates.

These two drugs together are taking the revenue baton from Humira, illustrating how portfolio rotation can stabilize overall company performance even as a legacy product declines.

Analyst response and valuation implications

Following the results, several sell-side firms adjusted their views upward. Notable moves included Morgan Stanley raising its price target and Canaccord increasing its target as well. These revisions reflect greater confidence that AbbVie’s newer immunology assets can sustain growth and margin expansion.

Upgrades and what they mean

Analyst upgrades typically tighten investor focus on execution. In AbbVie’s case, the upgrades highlight two practical implications:

• Near-term: Improved sentiment can support the stock if guidance continues to trend positively and quarter-to-quarter growth remains consistent.
• Long-term: Price-target increases signal expectations that Skyrizi and Rinvoq will offset Humira decline sufficiently to preserve free cash flow and support dividends and buybacks.

Operational developments that directly affect ABBV

Beyond quarterly numbers, AbbVie disclosed tangible strategic actions that reduce execution uncertainty and support capacity for growth-stage assets.

Regulatory filings

AbbVie has submitted regulatory applications for additional indications, including potential approvals that would broaden Rinvoq’s and Skyrizi’s addressable populations. These filings matter because label expansions translate into incremental revenue levers without proportionate increases in marketing overhead.

Manufacturing investment

The company has committed to a roughly $1.4 billion manufacturing campus in North Carolina. This investment is a practical bet on scale: more internal capacity eases supply constraints for high-demand biologics and reduces reliance on third-party supply chains — a positive for both margin control and launch reliability.

Risks that remain concrete

AbbVie’s trajectory is no longer dependent solely on Humira outcomes, but tangible risks persist and should be acknowledged when evaluating ABBV stock:

• Humira erosion continues to subtract from total revenue; the pace matters for near-term free cash flow.
• Pipeline and regulatory execution risk—some filings still face review timelines and outcome uncertainty.
• Valuation sensitivity—upgrades are offset by high expectations, and any execution slip could pressure multiples.

These are concrete considerations rooted in disclosed data and actions rather than speculation.

Conclusion

AbbVie’s most recent week of developments offers a clear narrative: management is executing a planned transition from Humira to a growing immunology franchise. The Q1 beat and raised adjusted EPS guidance were driven by strong Skyrizi and Rinvoq sales, and analyst upgrades followed. Complementary moves — regulatory submissions that could expand indications and a $1.4 billion manufacturing campus — strengthen AbbVie’s operational foundation. For investors, ABBV’s outlook now hinges on continued uptake of newer immunology drugs and disciplined execution of capacity and regulatory initiatives.

Data points in this article are drawn from AbbVie’s recent quarterly release and reporting by major financial outlets during the past week.